SCHEDULE: FMR LLC Discloses Stake in Foghorn Therapeutics

FMR LLC and Abigail P. Johnson report beneficial ownership of 11.6% of Foghorn Therapeutics Inc. common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Foghorn Therapeutics Inc. common stock.
• As of March 31, 2026, the total number of shares beneficially owned is 6,792,356.
• This represents 11.6% of the class of securities.
• FMR LLC is classified as an Investment Adviser (IA), and Fidelity Management Trust Company is classified as a Bank (BK).
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC.
• A shareholders' voting agreement among Series B voting common shareholders of FMR LLC may deem the Johnson family group as a controlling group with respect to FMR LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of beneficial ownership by a major financial institution and does not inherently signal positive or negative performance for the company itself.

Positives

• Significant beneficial ownership stake (11.6%) reported by FMR LLC and Abigail P. Johnson in Foghorn Therapeutics Inc.
• The filing indicates a stable ownership structure with clear reporting entities.
• The reporting is up-to-date as of March 31, 2026.

Risks

• The filing does not contain specific forward-looking statements or risk factors related to Foghorn Therapeutics Inc.'s business operations, as it is a beneficial ownership disclosure.
• Potential for changes in beneficial ownership, which could impact the stock price, although no immediate changes are indicated.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Foghorn Therapeutics Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson signifies a substantial institutional investment in Foghorn Therapeutics Inc., a biotechnology company. Such filings are common for large asset managers and indicate a significant position, potentially influencing market perception and trading activity.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's stake, which can be viewed positively by some shareholders as a sign of confidence, but also raises questions about potential future influence on company strategy.
• Management: The presence of a large institutional holder like FMR LLC may influence management decisions and strategic direction.
• Market Participants: This filing provides transparency to the market regarding significant ownership, impacting trading strategies and analysis.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any changes in their beneficial ownership of Foghorn Therapeutics Inc. common stock as required by SEC regulations.

Key Dates

Keywords

Foghorn Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Fidelity Management Trust Company, SEC Filing